Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yan Gong is active.

Publication


Featured researches published by Yan Gong.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2014

Cytochrome P450 2C8 ω3-Long-Chain Polyunsaturated Fatty Acid Metabolites Increase Mouse Retinal Pathologic Neovascularization—Brief Report

Zhuo Shao; Zhongjie Fu; Andreas Stahl; Jean-Sebastien Joyal; Colman J. Hatton; Aimee Juan; Christian G. Hurst; Lucy Evans; Zhenghao Cui; Dorothy T. Pei; Yan Gong; Dan Xu; Katherine Tian; Hannah H Bogardus; Matthew L. Edin; Fred B. Lih; Przemyslaw Sapieha; Jing Chen; Dipak Panigrahy; Ann Hellström; Darryl C. Zeldin; Lois E. H. Smith

Objective— Regulation of angiogenesis is critical for many diseases. Specifically, pathological retinal neovascularization, a major cause of blindness, is suppressed with dietary &ohgr;3-long-chain polyunsaturated fatty acids (&ohgr;3LCPUFAs) through antiangiogenic metabolites of cyclooxygenase and lipoxygenase. Cytochrome P450 epoxygenases (CYP2C8) also metabolize LCPUFAs, producing bioactive epoxides, which are inactivated by soluble epoxide hydrolase (sEH) to transdihydrodiols. The effect of these enzymes and their metabolites on neovascularization is unknown. Approach and Results— The mouse model of oxygen-induced retinopathy was used to investigate retinal neovascularization. We found that CYP2C (localized in wild-type monocytes/macrophages) is upregulated in oxygen-induced retinopathy, whereas sEH is suppressed, resulting in an increased retinal epoxide:diol ratio. With a &ohgr;3LCPUFA-enriched diet, retinal neovascularization increases in Tie2-driven human-CYP2C8–overexpressing mice (Tie2-CYP2C8-Tg), associated with increased plasma 19,20-epoxydocosapentaenoic acid and retinal epoxide:diol ratio. 19,20-Epoxydocosapentaenoic acids and the epoxide:diol ratio are decreased with overexpression of sEH (Tie2-sEH-Tg). Overexpression of CYP2C8 or sEH in mice does not change normal retinal vascular development compared with their wild-type littermate controls. The proangiogenic role in retina of CYP2C8 with both &ohgr;3LCPUFA and &ohgr;6LCPUFA and antiangiogenic role of sEH in &ohgr;3LCPUFA metabolism were corroborated in aortic ring assays. Conclusions— Our results suggest that CYP2C &ohgr;3LCPUFA metabolites promote retinal pathological angiogenesis. CYP2C8 is part of a novel lipid metabolic pathway influencing retinal neovascularization.


Biochimica et Biophysica Acta | 2016

Review: adiponectin in retinopathy.

Zhongjie Fu; Yan Gong; Chatarina Löfqvist; Ann Hellström; Lois E. H. Smith

Neovascular eye diseases are a major cause of blindness including retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration in which new vessel formation is driven by hypoxia or metabolic abnormalities affecting the fuel supply. White-adipose-tissue derived adipokines such as adiponectin modulate metabolic responses. Increasing evidence shows that lack of adiponectin may result in retinal neovascularization. Activation of the adiponectin pathway may in turn restore energy metabolism, to suppress the drive for compensatory but ultimately pathological neovessels of retinopathy. In this review, we will summarize our current knowledge of the role of adiponectin in eye diseases of premature infants, diabetic patients as well as the elderly. Further investigations in this field are likely to lead to new preventative approaches for these diseases.


EBioMedicine | 2016

Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis

Yan Gong; Zhuo Shao; Zhongjie Fu; Matthew L. Edin; Ye Sun; Raffael Liegl; Zhongxiao Wang; Chi-Hsiu Liu; Samuel Burnim; Steven Meng; Fred B. Lih; John Paul SanGiovanni; Darryl C. Zeldin; Ann Hellström; Lois E. H. Smith

Neovascular eye diseases including retinopathy of prematurity, diabetic retinopathy and age-related-macular-degeneration are major causes of blindness. Fenofibrate treatment in type 2 diabetes patients reduces progression of diabetic retinopathy independent of its peroxisome proliferator-activated receptor (PPAR)α agonist lipid lowering effect. The mechanism is unknown. Fenofibrate binds to and inhibits cytochrome P450 epoxygenase (CYP)2C with higher affinity than to PPARα. CYP2C metabolizes ω-3 long-chain polyunsaturated fatty acids (LCPUFAs). While ω-3 LCPUFA products from other metabolizing pathways decrease retinal and choroidal neovascularization, CYP2C products of both ω-3 and ω-6 LCPUFAs promote angiogenesis. We hypothesized that fenofibrate inhibits retinopathy by reducing CYP2C ω-3 LCPUFA (and ω-6 LCPUFA) pro-angiogenic metabolites. Fenofibrate reduced retinal and choroidal neovascularization in PPARα-/-mice and augmented ω-3 LCPUFA protection via CYP2C inhibition. Fenofibrate suppressed retinal and choroidal neovascularization in mice overexpressing human CYP2C8 in endothelial cells and reduced plasma levels of the pro-angiogenic ω-3 LCPUFA CYP2C8 product, 19,20-epoxydocosapentaenoic acid. 19,20-epoxydocosapentaenoic acid reversed fenofibrate-induced suppression of angiogenesis ex vivo and suppression of endothelial cell functions in vitro. In summary fenofibrate suppressed retinal and choroidal neovascularization via CYP2C inhibition as well as by acting as an agonist of PPARα. Fenofibrate augmented the overall protective effects of ω-3 LCPUFAs on neovascular eye diseases.


Arteriosclerosis, Thrombosis, and Vascular Biology | 2016

Cytochrome P450 Oxidase 2C Inhibition Adds to ω-3 Long-Chain Polyunsaturated Fatty Acids Protection Against Retinal and Choroidal Neovascularization

Yan Gong; Zhongjie Fu; Matthew L. Edin; Chi-Hsiu Liu; Zhongxiao Wang; Zhuo Shao; Thomas Fredrick; Nicholas Saba; Peyton Morss; Samuel Burnim; Steven Meng; Fred B. Lih; Kin Sing Stephen Lee; Elizabeth P. Moran; John Paul SanGiovanni; Ann Hellström; Bruce D. Hammock; Darryl C. Zeldin; Lois E. H. Smith

Objective—Pathological ocular neovascularization is a major cause of blindness. Increased dietary intake of &ohgr;-3 long-chain polyunsaturated fatty acids (LCPUFA) reduces retinal neovascularization and choroidal neovascularization (CNV), but &ohgr;-3 LCPUFA metabolites of a major metabolizing pathway, cytochrome P450 oxidase (CYP) 2C, promote ocular pathological angiogenesis. We hypothesized that inhibition of CYP2C activity will add to the protective effects of &ohgr;-3 LCPUFA on neovascular eye diseases. Approach and Results—The mouse models of oxygen-induced retinopathy and laser-induced CNV were used to investigate pathological angiogenesis in the retina and choroid, respectively. The plasma levels of &ohgr;-3 LCPUFA metabolites of CYP2C were determined by mass spectroscopy. Aortic ring and choroidal explant sprouting assays were used to investigate the effects of CYP2C inhibition and &ohgr;-3 LCPUFA–derived CYP2C metabolic products on angiogenesis ex vivo. We found that inhibition of CYP2C activity by montelukast added to the protective effects of &ohgr;-3 LCPUFA on retinal neovascularization and CNV by 30% and 20%, respectively. In CYP2C8-overexpressing mice fed a &ohgr;-3 LCPUFA diet, montelukast suppressed retinal neovascularization and CNV by 36% and 39% and reduced the plasma levels of CYP2C8 products. Soluble epoxide hydrolase inhibition, which blocks breakdown and inactivation of CYP2C &ohgr;-3 LCPUFA–derived active metabolites, increased oxygen-induced retinopathy and CNV in vivo. Exposure to selected &ohgr;-3 LCPUFA metabolites of CYP2C significantly reversed the suppression of both angiogenesis ex vivo and endothelial cell functions in vitro by the CYP2C inhibitor montelukast. Conclusions—Inhibition of CYP2C activity adds to the protective effects of &ohgr;-3 LCPUFA on pathological retinal neovascularization and CNV.


Angiogenesis | 2018

Consensus guidelines for the use and interpretation of angiogenesis assays

Patrycja Nowak-Sliwinska; Kari Alitalo; Elizabeth Allen; Andrey Anisimov; Alfred C. Aplin; Robert Auerbach; Hellmut G. Augustin; David O. Bates; Judy R. van Beijnum; R. Hugh F. Bender; Gabriele Bergers; Andreas Bikfalvi; Joyce Bischoff; Barbara C. Böck; Peter C. Brooks; Federico Bussolino; Bertan Cakir; Peter Carmeliet; Daniel Castranova; Anca M. Cimpean; Ondine Cleaver; George Coukos; George E. Davis; Michele De Palma; Anna Dimberg; Ruud P.M. Dings; Valentin Djonov; Andrew C. Dudley; Neil Dufton; Sarah Maria Fendt

AbstractThe formation of new blood vessels, or angiogenesis, is a complex process that plays important roles in growth and development, tissue and organ regeneration, as well as numerous pathological conditions. Angiogenesis undergoes multiple discrete steps that can be individually evaluated and quantified by a large number of bioassays. These independent assessments hold advantages but also have limitations. This article describes in vivo, ex vivo, and in vitro bioassays that are available for the evaluation of angiogenesis and highlights critical aspects that are relevant for their execution and proper interpretation. As such, this collaborative work is the first edition of consensus guidelines on angiogenesis bioassays to serve for current and future reference.n


The American Journal of Clinical Nutrition | 2017

ω-3 and ω-6 long-chain PUFAs and their enzymatic metabolites in neovascular eye diseases

Yan Gong; Zhongjie Fu; Raffael Liegl; Jing Chen; Ann Hellström; Lois E. H. Smith

Neovascular eye diseases, including retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration, threaten the visual health of children and adults. Current treatment options, including anti-vascular endothelial growth factor therapy and laser retinal photocoagulation, have limitations and are associated with adverse effects; therefore, the identification of additional therapies is highly desirable. Both clinical and experimental studies show that dietary ω-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFAs) reduce retinal and choroidal angiogenesis. The ω-3 LC-PUFA metabolites from 2 groups of enzymes, cyclooxygenases and lipoxygenases, inhibit [and the ω-6 (n-6) LC-PUFA metabolites promote] inflammation and angiogenesis. However, both of the ω-3 and the ω-6 lipid products of cytochrome P450 oxidase 2C promote neovascularization in both the retina and choroid, which suggests that inhibition of this pathway might be beneficial. This review summarizes our current understanding of the roles of ω-3 and ω-6 LC-PUFAs and their enzymatic metabolites in neovascular eye diseases.


EBioMedicine | 2017

Sema3f Protects Against Subretinal Neovascularization In Vivo

Ye Sun; Raffael Liegl; Yan Gong; Anima Bühler; Bertan Cakir; Steven Meng; Samuel Burnim; Chi-Hsiu Liu; Tristan Reuer; Peipei Zhang; Johanna M. Walz; Franziska Ludwig; Clemens Lange; Hansjürgen T. Agostini; Daniel Böhringer; Günther Schlunck; Lois E. H. Smith; Andreas Stahl

Pathological neovascularization of the outer retina is the hallmark of neovascular age-related macular degeneration (nAMD). Building on our previous observations that semaphorin 3F (Sema3f) is expressed in the outer retina and demonstrates anti-angiogenic potential, we have investigated whether Sema3f can be used to protect against subretinal neovascularization in two mouse models. Both in the very low-density lipid-receptor knockout (Vldlr−/−) model of spontaneous subretinal neovascularization as well as in the mouse model of laser-induced choroidal neovascularization (CNV), we found protective effects of Sema3f against the formation of pathologic neovascularization. In the Vldlr−/− model, AAV-induced overexpression of Sema3f reduced the size of pathologic neovascularization by 56%. In the laser-induced CNV model, intravitreally injected Sema3f reduced pathologic neovascularization by 30%. Combined, these results provide the first evidence from two distinct in vivo models for a use of Sema3f in protecting the outer retina against subretinal neovascularization.


Cell Reports | 2017

FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice

Zhongjie Fu; Yan Gong; Raffael Liegl; Zhongxiao Wang; Chi-Hsiu Liu; Steven Meng; Samuel Burnim; Nicholas Saba; Thomas Fredrick; Peyton Morss; Ann Hellström; Saswata Talukdar; Lois E. H. Smith

Pathological neovascularization, a leading cause of blindness, is seen in retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. Using a mouse model of hypoxia-driven retinal neovascularization, we find that fibroblast growth factor 21 (FGF21) administration suppresses, and FGF21 deficiency worsens, retinal neovessel growth. The protective effect of FGF21 against neovessel growth was abolished in adiponectin (APN)-deficient mice. FGF21 administration also decreased neovascular lesions in two models of neovascular age-related macular degeneration: very-low-density lipoprotein-receptor-deficient mice with retinal angiomatous proliferation and laser-induced choroidal neovascularization. FGF21 inhibited tumor necrosis α (TNF-α) expression but did not alter Vegfa expression in neovascular eyes. These data suggest that FGF21 may be a therapeutic target for pathologic vessel growth in patients with neovascular eye diseases, including retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration.


Embo Molecular Medicine | 2018

Photoreceptor glucose metabolism determines normal retinal vascular growth

Zhongjie Fu; Chatarina Löfqvist; Raffael Liegl; Zhongxiao Wang; Ye Sun; Yan Gong; Chi-Hsiu Liu; Steven Meng; Samuel Burnim; Ivana Arellano; My T. Chouinard; Rubi Duran; Alexander Poblete; Steve Cho; James D. Akula; Michael Kinter; David Ley; Ingrid Hansen Pupp; Saswata Talukdar; Ann Hellström; Lois E. H. Smith

The neural cells and factors determining normal vascular growth are not well defined even though vision‐threatening neovessel growth, a major cause of blindness in retinopathy of prematurity (ROP) (and diabetic retinopathy), is driven by delayed normal vascular growth. We here examined whether hyperglycemia and low adiponectin (APN) levels delayed normal retinal vascularization, driven primarily by dysregulated photoreceptor metabolism. In premature infants, low APN levels correlated with hyperglycemia and delayed retinal vascular formation. Experimentally in a neonatal mouse model of postnatal hyperglycemia modeling early ROP, hyperglycemia caused photoreceptor dysfunction and delayed neurovascular maturation associated with changes in the APN pathway; recombinant mouse APN or APN receptor agonist AdipoRon treatment normalized vascular growth. APN deficiency decreased retinal mitochondrial metabolic enzyme levels particularly in photoreceptors, suppressed retinal vascular development, and decreased photoreceptor platelet‐derived growth factor (Pdgfb). APN pathway activation reversed these effects. Blockade of mitochondrial respiration abolished AdipoRon‐induced Pdgfb increase in photoreceptors. Photoreceptor knockdown of Pdgfb delayed retinal vascular formation. Stimulation of the APN pathway might prevent hyperglycemia‐associated retinal abnormalities and suppress phase I ROP in premature infants.


BMC Biology | 2017

PPARα is essential for retinal lipid metabolism and neuronal survival

Elizabeth A. Pearsall; Rui Cheng; Kelu Zhou; Yusuke Takahashi; H. Greg Matlock; Shraddha S. Vadvalkar; Younghwa Shin; Thomas Fredrick; Marin L. Gantner; Steven Meng; Zhongjie Fu; Yan Gong; Michael Kinter; Kenneth M. Humphries; Luke I. Szweda; Lois E. H. Smith; Jian Xing Ma

BackgroundPeroxisome proliferator activated receptor-alpha (PPARα) is a ubiquitously expressed nuclear receptor. The role of endogenous PPARα in retinal neuronal homeostasis is unknown. Retinal photoreceptors are the highest energy-consuming cells in the body, requiring abundant energy substrates. PPARα is a known regulator of lipid metabolism, and we hypothesized that it may regulate lipid use for oxidative phosphorylation in energetically demanding retinal neurons.ResultsWe found that endogenous PPARα is essential for the maintenance and survival of retinal neurons, with Pparα-/- mice developing retinal degeneration first detected at 8xa0weeks of age. Using extracellular flux analysis, we identified that PPARα mediates retinal utilization of lipids as an energy substrate, and that ablation of PPARα ultimately results in retinal bioenergetic deficiency and neurodegeneration. This may be due to PPARα regulation of lipid transporters, which facilitate the internalization of fatty acids into cell membranes and mitochondria for oxidation and ATP production.ConclusionWe identify an endogenous role for PPARα in retinal neuronal survival and lipid metabolism, and furthermore underscore the importance of fatty acid oxidation in photoreceptor survival. We also suggest PPARα as a putative therapeutic target for age-related macular degeneration, which may be due in part to decreased mitochondrial efficiency and subsequent energetic deficits.

Collaboration


Dive into the Yan Gong's collaboration.

Top Co-Authors

Avatar

Lois E. H. Smith

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Zhongjie Fu

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Chi-Hsiu Liu

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Steven Meng

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Samuel Burnim

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Zhongxiao Wang

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Ann Hellström

University of Gothenburg

View shared research outputs
Top Co-Authors

Avatar

Raffael Liegl

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Thomas Fredrick

Boston Children's Hospital

View shared research outputs
Top Co-Authors

Avatar

Ye Sun

Boston Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge